Bupivacaine hydrochloride is used for inducing local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
Bupivacaine Hydrochloride Injection is available in six single-dose and two multi-dose latex-free vials.
Bupivacaine also features the company’s PreventIV MeasuresSM packaging and labeling design to reduce medication errors.
Sagent has developed Bupivacaine in collaboration with Strides Arcolab who will be responsible to develop and supply injectable products that Sagent will market in the US.